Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Elliot Dean Hoops, serving as General Counsel and Secretary for MP Materials Corp, finalized a stock sale valued at approximately $533,606, disposing of 7,823 shares at varied prices in late January 2026. This transaction adhered to a previously established Rule 10b5-1 trading schedule. Concurrently, MP Materials has reported important progress in …
Christopher Gibson, director at Recursion Pharmaceuticals, sold 40,000 shares of Class A Common Stock in January 2026, coinciding with a stock conversion of Class B to Class A shares. Meanwhile, the company disclosed promising interim results from its Phase 1b/2 TUPELO trial assessing the investigational drug REC-4881, showing substantial reduction…
Jonathan Zalevsky, Chief Research and Development Officer at biopharmaceutical company Nektar Therapeutics, sold 3,867 company shares worth approximately $137,935 at an average price of $35.67 on January 20, 2026. This transaction follows recent mixed results from Nektar's Phase 2b REZOLVE-AA trial for alopecia areata, which narrowly missed its pri…
Campbell Bradley L., the President and CEO of Amicus Therapeutics, completed a sale of 75,000 shares on January 20, 2026, generating approximately $1.07 million. Alongside this, he exercised options to acquire an equal number of shares. This insider activity coincides with a strong market performance for Amicus shares and the announcement of an all…
EverCommerce Inc. CEO Eric Richard Remer completed two stock sale transactions in late January 2026, liquidating approximately $171,000 in shares through a structured trading plan. The company recently announced third-quarter 2025 results reflecting slight revenue gains yet received cautious analyst reactions, highlighting a balanced risk landscape…
Jay L. Schottenstein, serving as Executive Chairman and CEO of American Eagle Outfitters (NASDAQ:AEO), executed a series of stock sales totaling nearly $26.8 million by divesting 1,049,679 shares within a three-day period. Concurrently, the company has adjusted its fourth-quarter operating income forecast upward and announced a strategic global par…
John Alexander Kelly, CFO of Precision Biosciences Inc., sold over 15,000 shares at $4.03 each on January 21, 2026, amounting to just above $61,000. Concurrently, Kelly vested a substantial number of restricted stock units the previous day. Precision Biosciences continues to make progress in its gene editing programs and financial positioning amids…
Dario Scimeca, the General Counsel and Secretary of Precision BioSciences (NASDAQ:DTIL), executed the sale of 8,854 of the company’s common shares for a total of $35,681 on January 21, 2026. This transaction comes while the stock trades slightly above the sale price and amid an InvestingPro assessment rating the shares as overvalued. Concurrently, …
Precision Biosciences Inc's Chief Research Officer, Smith J. Jefferson, recently sold over 10,000 shares of the company's stock while concurrently acquiring a larger number of shares from vested Restricted Stock Units. The company continues to move forward with key gene editing clinical trials and maintains strong liquidity after a recent capital r…
Mara Holdings CEO Frederick G. Thiel sold over 27,000 shares on January 20, 2026, netting approximately $297,000. The transaction was part of a pre-established trading plan, set against the backdrop of fluctuating cryptocurrency markets and varied analyst outlooks. Despite recent declines in Mara's stock tied to Bitcoin price weakness, the company’…
Abraham Ceesay, CEO of clinical-stage biotech firm Rapport Therapeutics, sold just over 10,900 shares valued at approximately $285,000 in two transactions under a pre-established trading plan. These dealings occur as the company expedites Phase 3 trials for its epilepsy drug RAP-219, earning favorable analyst responses and raising price targets for…
DraftKings Inc.'s Chief Legal Officer, Dodge R Stanton, recently undertook significant stock transactions involving both the sale of shares and the exercise of stock options. These actions took place against a backdrop of notable share price volatility, analyst optimism about the company’s potential profitability, and a fluctuating online sports be…
On January 20, 2026, Meta Platforms COO Javier Olivan sold a substantial portion of his Class A shares, signaling notable insider activity. Concurrently, regulatory approvals and analyst assessments are influencing perspectives on major tech and media firms, including Meta and ByteDance, impacting digital advertising and AI innovation sectors.
Frank Slootman, a director at Snowflake Inc., recently sold 180,070 shares valued at approximately $41.35 million, with transactions occurring in January 2026. Concurrently, Slootman exercised stock options to acquire additional shares at a modest price. The company's market activities coincide with its announced acquisition of Observe to bolster A…
James Francis Kessler, CEO of Rb Global, executed a sale of 20,742 shares valuing over $2.3 million while also exercising stock options, against the backdrop of the company's better-than-expected third quarter and a favorable rating upgrade from National Bank Financial. The company has further announced a quarterly dividend, reflecting confidence i…
Jennifer L. Wong, Chief Operating Officer of Reddit, Inc., sold 31,939 shares of the company's Class A Common Stock totaling approximately $8.8 million. The sales, conducted under a Rule 10b5-1 trading plan, took place on January 20, 2026, with prices ranging from $219.13 to $228.47 per share despite a recent 6.21% stock dip. Analysts offer varying…
Thomas Dean Fountain, EVP of Global Services & Strategy at F5 Networks, divested 1,110 shares valued at approximately $291,630 under a pre-established trading plan. Concurrently, F5 is advancing product innovation with newly launched AI security solutions and shows favorable analyst sentiment amid upcoming earnings.
Bluescape Riley Exploration Holdings LLC, holding a 10% stake in Riley Exploration Permian, finalized the sale of 165,484 shares from January 20 to 22, generating proceeds of approximately $4.49 million. This insider transaction coincides with Riley Exploration's recent announcements of a quarterly dividend, midstream asset divestiture, and a subst…
Jon A. Olson, a director at Rocket Lab Corporation, divested 14,505 shares under a Rule 10b5-1 trading plan, totaling $1.38 million in proceeds, as the company’s stock neared a 52-week peak. Rocket Lab shares have surged nearly 200% in the past year, bolstered by successful launches and significant contract wins. Several prominent financial institu…
Sheldon Richard Bentley, founder of Cloudastructure, Inc., completed the sale of 50,000 shares of the company's Class A Common Stock over two days in January 2026, amounting to $42,000. The transactions stemmed from a Rule 10b5-1 trading arrangement initiated in August 2025. Meanwhile, Cloudastructure advances its security technology portfolio, inc…
Between late November and mid-December 2025, a consortium known as the Endeavor Investor Group, encompassing Endeavor Blockchain, LLC, PM Squared LLC, Cody Smith, and Joshua Allen Kilgore, acquired $4.38 million worth of Mawson Infrastructure Group Inc. (NASDAQ:MIGI) shares. The transactions occurred within a broad price spectrum of $4.03 to $12.00…
Stephanie Ann Sentell, Chief Operations Officer at Shake Shack Inc., finalized the sale of 200 shares of Class A common stock on January 20, 2026, valued at $19,838 under a pre-established trading plan. The transaction occurred despite the company’s recent fourth-quarter revenue falling slightly below analyst expectations. Shake Shack also announce…
Jeff Benck, CEO of Benchmark Electronics, sold 15,000 shares over two days, yielding proceeds of approximately $753,576 as the company’s stock traded close to its 52-week high. These sales, made under a prearranged plan, come amid strong recent stock gains, upcoming earnings reports, and notable corporate leadership transitions.
Terilyn J. Monroe, Chief People Officer of Guardant Health, divested 8,571 shares valued at approximately $977,900 on January 21, 2026, amid a backdrop of encouraging FDA approval and positive analyst sentiment. The transactions occurred at prices ranging from $112.34 to $115.70 per share. Guardant Health has recently achieved FDA clearance for its…
MediaAlpha, Inc. director Yi Steven sold 24,000 shares over three days, accumulating proceeds close to $267,432. The sales coincided with the company’s strong financial performance in Q3 2025, prompting increased analyst price targets and corporate governance updates including board changes and bylaw amendments.
